Market Size & Trends
The global veterinary intravenous solutions market size was estimated at USD 1.45 billion in 2024 and is expected to grow at a CAGR of 6.21% from 2025 to 2030. Key factors driving the market growth are the increasing incidence of animal diseases & dehydration, the growing adoption of pet insurance, and the increase in pet ownership & pet expenditure.
Key Takeaways
North America was leading the market and held a revenue share of more than 38.09% in 2024.
The U.S. market is growing steadily due to the increasing prevalence of chronic diseases in companion animals.
From a product segment point of view, the isotonic crystalloids segment was leading the market and held a revenue share of more than 42.00% in 2024.
Based on animal type segment, the companion animal segment led the market with a revenue share of more than 58.0% in 2024.
Based on indication segment, the diabetic ketoacidosis segment led the market for veterinary intravenous (IV) solutions with a revenue share of more than 28.0% in 2024.
For example, as stated in an article by International Cat Care, in February 2025, CKD may strike cats at any age but is most commonly diagnosed in middle-aged to older cats, especially those aged over 7 years. It is projected that about 20% to 50% of cats aged over 15 years have some degree of CKD.
The increasing popularity of pet insurance across the globe is proving to be a major factor in propelling demand for veterinary intravenous (IV) solutions. With escalating veterinary expenditure, pet insurance aids owners in coping with costs and choosing superior quality treatments, particularly in severe care cases where IV therapy becomes inevitable. IV treatment is a standard in the management of an array of pet health ailments like dehydration, infections, post-operative recovery, kidney diseases, and exposure to toxins, often included in pet insurance policies. Such reimbursement access makes pet owners opt for intensive care measures that involve IV delivery instead of postponing or forgoing such due to financial reasons.
For instance, as per an article released by the North American Pet Health Insurance Association, Inc. (NAPHIA) in April 2025, about 7.03 million pets were covered in North America as of the end of 2024, a 12.2% rise compared to the 6.25 million covered pets in 2023. Moreover, an article by PetMD in 2024 points out that horse insurance can cost between USD 300 and USD 3,000, with minimal plans usually including diagnostic tests, treatments, and surgeries, including those connected with chronic conditions. As pet owners increasingly focus on the wellbeing of their dogs and horses, these trends will keep the veterinary intravenous (IV) solutions market growing strong.
Additionally, dehydration is a widespread and life-threatening disease in animals and livestock. For example, as per a report brought out by Hindustan Times, in February 2025, in January 2025, 177 dehydrated animals comprising 158 birds and 19 mammals were admitted to the Transit Treatment Centre (TTC) in Bavdhan, which is a significant rise in such cases. A report by the RESQ Charitable Trust, a non-profit organization operating in collaboration with the Maharashtra Forest Department, puts these admissions down to weather-related illness, dehydration being one of the main concerns. Such conditions usually require prompt rehydration, correction of electrolytes, and the administration of drugs, which can be well addressed via IV therapy.
Market Concentration & Characteristics
The market for IV solutions is moderately concentrated, and the growth of the market is speeding up. Growing surgical procedures in animals are one of the primary reasons behind the growth of the market. As more and more pets and livestock are being operated on from simple procedures such as spaying to intricate ones such as tumor removals and orthopedic surgeries, the need for supportive treatment like IV fluids has grown exponentially. For example, as per the article by Dr. Kelly's Surgical Unit that was published in February 2024, 80% of dogs have already been spayed or neutered. Intravenous fluids are equally important during surgery and after recovery, as they ensure hydration, stabilize electrolytes, administer medicine, and support recovery.
Moderate to a high degree of innovations is noted in the market, owing to technological developments as well as launching new products. For example, in March of 2025, Laboratories Alfa SRL launched a solution which contains 5.5% dextrose with 0.9% sodium chloride. It is an intravenous solution which is used in the replacement of fluid and electrolytes, providing a balanced solution for veterinary purposes. These solutions are sterile, non-pyrogenic, and single-dose. They do not have any antimicrobial agents and must be discarded if not used immediately upon opening. The products are offered in different concentrations and pack sizes to address clinical requirements.
There is limited mergers and acquisitions activity in the market. With consolidation among companies, they can share resources to advance research and development, which results in the launch of more advanced and cheaper solutions. M&A also increases market coverage, allowing for improved distribution channels and exposure to a wider customer base, such as veterinary clinics and hospitals.
Regulatory systems play a vital part in framing the marketplace by directly impacting product development, approval duration, quality requirements, and market entry. Bodies like the FDA's Center for Veterinary Medicine (CVM) in the United States and the European Medicines Agency (EMA) in Europe require strict adherence to Good Manufacturing Practices (GMP) and pharmacovigilance standards to guarantee the safety and efficacy of intravenous (IV) solutions given to animals.
The market substitutes have a moderate to strong effect by affecting treatment decisions, pricing, and innovation. Substitutes like oral rehydration solution, subcutaneous fluid therapy, and new drug delivery systems (e.g., transdermal patches or injectables) provide less invasive, more convenient, and sometimes less expensive alternatives, especially in non-critical or outpatient care. This can cut into demand for conventional IV solutions in everyday veterinary practice.
New markets expansion provides improved access of IV solutions to a broader set of veterinary clinics, animal hospitals, and healthcare professionals. Market penetration in developing economies with expanding pet populations and livestock sectors results from this expansion, increasing demand for veterinary services.
Product Insights
The isotonic crystalloids segment held the largest market share and registered a revenue share of more than 42.00% in 2024. Isotonic crystalloids are widely employed in veterinary medicine for the treatment of numerous diseases and conditions by re-establishing fluid and electrolyte balance. Isotonic crystalloids are osmolally equivalent to blood plasma and therefore do not induce tremendous fluid shifts between compartments. Such solutions have the same osmolality as blood plasma, thus being useful in the management of dehydration, shock, and acid-base disturbances. Isotonic solutions have the same osmolality as the extracellular fluid. Consequently, they are excellent rehydration and maintenance solutions, especially since they can be administered intravenously, intraosseously, subcutaneously, and intraperitoneally. Lactated Ringer's, 0.9 percent (normal or physiologic) saline, Ringer's, acetated Ringer's, and 2.5% dextrose in 0.45% saline and Plasma-Lyte A are some of the widely used isotonic solutions.
The dextrose solutions segment is expected to advance at the quickest CAGR of around 7.26% from 2025 to 2030. Dextrose, or glucose, is a sugar that can be given intravenously to provide an easily accessible source of energy to the body of an animal. Veterinary dextrose solutions also offer hydration support. By giving intravenous dextrose solutions, the water comes with the glucose, and this aids in ensuring that animals with dehydration or who cannot take sufficient water are well-hydrated. 5% dextrose is the most frequently employed concentration, and it is isotonic and will frequently be given alone or with other electrolytes such as sodium chloride or lactate. For example, the combinations of 5% dextrose with 0.33% sodium chloride or lactated Ringer's solution are designed to correct both fluid loss and electrolyte loss. These combinations correct dehydration while simultaneously offering necessary nutrition.
Animal Type Insights
The companion animal segment led the market with a revenue share of more than 58.0% in 2024. Companion animals, such as dogs and cats, are regularly kept as pets in most homes. The high pet ownership rate is responsible for the vast demand for veterinary IV fluids since these pets tend to need intravenous treatment of various medical conditions, surgical procedures, or critical care cases. As per the 2024 statistics of the American Pet Products Association (APPA), the U.S. has a population of more than 65.1 million dogs, the highest number of owned pets in any country. In addition to the U.S., more than 32% of the households in Asia have a dog, as per a survey conducted by Rakuten Insights in 2021.
The production animal segment is anticipated to demonstrate the highest growth rate over the forecast period. Veterinary intravenous (IV) therapy is a vital element in the care of production animals like cattle, sheep, goats, and pigs. They are prone to dehydration and metabolic imbalance resulting from diseases in the gastrointestinal tract, heat stress, and nutritional diseases. Intravenous solutions allow for quick and regulated fluid and electrolyte repletion, which is crucial for stabilizing these animals. Since the incidence of mouth disease among farm animals is on the rise. For instance, cloven-footed animals like cattle, pigs, sheep, and goats are most frequently infected with the highly contagious viral infection called foot-and-mouth disease. Although it primarily brings about lesions in the foot and the mouth, the disease could spread very quickly and result in a substantial economic burden through movement and trade restrictions on animals.
Indication Insights
The diabetic ketoacidosis application led the market for veterinary intravenous (IV) solutions with a market revenue share of more than 28.0% in 2024. The incidence of DKA in animals is directly proportional to the incidence of diabetes mellitus in animals. Diabetes mellitus, which may either be type 1 or type 2, is comparatively prevalent in companion animals, namely dogs and cats. The prevalence of diabetes among animals has also been on the rise over the last few years, which may result in an increased number of DKA cases. Intravenous fluids play a central role in treatment of diabetic ketoacidosis (DKA) among animals. DKA is an unsafe and occasionally deadly complication of diabetes mellitus that is characterized by metabolic acidosis, ketosis, and hyperglycemia. The intravenous fluid therapy for DKA in animals is designed to reverse dehydration, restore electrolytes, and deliver glucose and insulin therapy.
The others segment will have the highest rate of growth of more than 6.49% during the forecast period. Vomiting, diarrhea, and dehydration are included in the others segment. Diarrhea is a common presenting condition of companion animal practice. Young puppies are much more prone to both diarrhea and vomiting, and the incidence of developing diarrhea decreases from 16% in 7- to 12-week-old puppies to 5.4% in 12- to 18-month-old dogs. Veterinary intravenous (IV) fluids play a vital role in correcting dehydration and electrolyte disturbances due to diarrhea in animals. Isotonic crystalloids such as Lactated Ringer's and 0.9% Normal Saline are often utilized to reestablish fluid equilibrium and treat acidosis.
End Use Insight
Veterinary hospital segment had the maximum market share in 2024 due to an increased number of pet owners visiting hospitals for treatment. IV fluid therapy is a core part of patient management that veterinary hospitals commonly use. Veterinary hospitals have the capabilities to manage emergency cases and provide intensive and immediate care to animals in serious conditions. IV solutions are often applied in case of emergencies to stabilize the patient, manage shock, and provide quick delivery of medications and fluids that a patient might need. IV solutions are important in the administration of intravenous solutions, which are important in the treatment of a vast range of medical problems in animals. IV solutions are applied to manage dehydration, shock, electrolyte imbalances, as well as manage the delivery of medications and nutrients.
The others segment is expected to register the highest CAGR during the forecast period. Veterinary home care environments refer to the delivery of medical treatment and care to animals within the comfort of their homes and not in a conventional veterinary clinic or hospital environment. Veterinary professionals attend to the pet owner in the latter environment to deliver several kinds of healthcare services, including veterinary IV solution administration. Veterinary home care provides comfort and convenience to the animals and their owners. It breaks the stress and anxiety that comes with taking animals to a clinic and enables them to be treated at home.
Regional Insights
North America led the market and held a revenue share of more than 38.09% in 2024. The demand is driven mainly by the increasing incidence of acute and chronic diseases in companion animals. Diseases like chronic kidney disease (CKD), gastrointestinal diseases, trauma, and infectious diseases require supportive fluid therapy, and hence IV solutions are a necessary treatment component. To illustrate, CKD occurs in as much as 80% of cats that are more than 15 years of age in the U.S., and IV fluids play a crucial role in volume control and toxin removal. Parvovirus in puppies also tends to necessitate forceful fluid therapy to manage extreme dehydration and electrolyte disturbance. Such medical needs are driving consistent market growth in veterinary clinics and emergency facilities.
U.S. Veterinary Intravenous Solutions Market Trends
The American market is growing steadily, fueled by increasing rates of chronic disease among companion animals, including chronic kidney disease (CKD), gastrointestinal illness, and dehydrating stages. With more than 70 million pet dogs and 60 million pet cats in America, and an increasing population of older pets, the need for IV fluid therapy is growing. Moreover, this emergency and surgical care in veterinary practices consistently depends on IV solutions for anesthesia support, electrolyte management, and shock management.
Europe Veterinary Intravenous Solutions Market Trends
The European market for IV solutions is anticipated to develop at an aggressive pace given the increasing focus on innovative animal welfare, expanding advanced veterinary care, and chronic and infectious disease prevalence in livestock and companion animals. As estimated by the European Pet Food Industry Federation (FEDIAF), there were about 352 million pet animals in Europe in 2024, with increased veterinary consultations per pet because of enhanced awareness and outlays on pets' health. Veterinary clinics in nations such as Germany, France, and the UK are increasingly implementing IV fluid therapy in the treatment of dehydration, renal disease, and post-surgical conditions, specifically among older pet populations, driving demand for varied IV solution formulations including electrolytes, saline, and glucose.
The UK market for IV solutions is mainly fueled by the rising pet ownership rates and raised awareness of veterinary care. As per the Pet Food Manufacturers' Association (PFMA), there were roughly 59% of UK homes that had pets, with dogs and cats being the most popular. The increasing number of pets has directly contributed to demand for sophisticated veterinary treatments, including those involving IV solutions for critical illness, surgery, and treating chronic conditions. Veterinary clinics are being equipped with more facilities for administering fluid therapy, especially in light of the increasing incidence of kidney failure and diabetes in older pet populations.
Asia Pacific Veterinary Intravenous Solutions Market Trends
The Asia Pacific veterinary intravenous solutions market is showing rapid growth, led by the growing livestock population in the region, growing companion animal ownership, and the increasing rate of infectious diseases in animals. Nations such as India, China, Australia, and South Korea are experiencing growing demand for veterinary healthcare services, especially in the treatment of dehydration, electrolyte disturbances, and infections in livestock and pets. For example, India and China, two of the globe's major cattle and pig producers, have experienced recurrent cases of gastrointestinal diseases like calf diarrhea, swine dysentery, and avian enteritis, which have underscored the importance of IV fluid therapy to facilitate the recovery of animals and lower mortality rates.
The veterinary intravenous solutions market in India is experiencing rapid growth due to a steep rise in chronic and acute diseases in companion animals, most notably renal failure in dogs. As per a February 2025 article in the Times of India, Guru Angad Dev Veterinary and Animal Sciences University (GADVASU) in Ludhiana sees 6-7 new cases of canine renal failure each day, with several needing fluid therapy or dialysis. The underlying causes vary from inadequate diet (junk food, grapes, chocolates), sedentary lifestyle, and excessive use of human painkillers to infectious illnesses such as babesiosis and tick fever. In such instances, intravenous fluid therapy is required to rehydrate, maintain kidney function, and eliminate toxins from the body.
Latin America Veterinary Intravenous Solutions Market Trends
Latin America's livestock industry is a key driver in the veterinary IV solutions demand. Brazil, for example, is a world leader in meat production with cattle slaughter hitting 34.06 million head in 2023, up 13.7% compared to the year before. Furthermore, poultry and swine industries also broke records with 6.28 billion chickens and 57.17 million pigs slaughtered, respectively. Such mass production requires sophisticated veterinary care, such as IV treatments, to deal with animal health effectively and maintain productivity.
The market for Brazil IV solutions is following a steady growth trend, fuelled by the widespread occurrence of infectious diseases like neonatal calf diarrhea, in addition to Brazil's large cattle sector. Diarrheal diseases, specifically rotavirus A (RVA) and bovine viral diarrhea virus (BVDV), pose significant threats to young calves and lead to economic losses through stunted growth rates, increased mortality, and elevated veterinary expenditures. A survey across Brazil's Midwest, South, and Southeast reported RVA in 27.4% of the diarrheic fecal samples of calves, the beef calves having a significantly higher infection rate (31.9%) than dairy calves (17.4%), while the Midwest region itself registered 39.4% RVA-positive cases. These data show the necessity for supportive therapies like IV fluid therapy to treat dehydration and stabilize infected animals at large.
Middle East & Africa Veterinary Intravenous Solutions Market Trends
The veterinary intravenous (IV) solutions market in the Middle East and Africa (MEA) region is growing steadily, driven by the expanding livestock sector, rising pet ownership, and increasing government investment in animal health infrastructure. Countries like Saudi Arabia, UAE, Kuwait, and South Africa have large livestock populations-Saudi Arabia alone has over 30 million livestock heads-necessitating IV treatments for dehydration, heat stress, and disease management, especially in arid climates.
The market in South Africa is experiencing notable growth. One of the primary drivers is the increasing prevalence of animal diseases such as infectious diseases, dehydration, and chronic conditions like kidney disease, which frequently require IV fluid therapy as part of treatment protocols. In both emergency and routine veterinary care, IV solutions are essential for managing dehydration, delivering medications, and supporting animals during surgical procedures or periods of critical illness. For example, outbreaks of diseases such as avian influenza in poultry and rising cases of chronic kidney disease in aging pets have increased the demand for supportive therapies like IV fluids to stabilize and treat affected animals.
Key Veterinary Intravenous Solutions Company Insights
The market is competitive and marked by the presence of key players. The key parameters affecting competition include a technological advancement. Additionally, to maintain market share and expand their product portfolios, leading companies are adopting strategies such as mergers and acquisitions, strategic partnerships, and the launch of innovative products.
Key Veterinary Intravenous Solutions Companies
The following are the leading companies in the IV solutions market. These companies collectively hold the largest market share and dictate industry trends.
- Merck & Co., Inc (Animal Health
- Dechra
- Animalcare Limited
- B. Braun Vet Care (B Braun SE)
- Elanco Animal Health Incorporated (Animal Health)
- Zoetis Inc.
Recent Developments
-
In June 2018, Sypharma Pty Ltd, an Australian pharmaceutical manufacturer, achieved a significant milestone with FDA approval for the distribution of its Hartmann’s IV solution in the United States. Marketed under its veterinary brand Sykes IV Lyte Injection (Electrolytes), this approval marks a strategic expansion of Sypharma’s global footprint in the animal health sector.
Veterinary Intravenous Solutions Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2025 |
USD 1.53 billion |
|
Revenue forecast in 2030 |
USD 2.07 billion |
|
Growth Rate |
CAGR of 6.21% from 2025 to 2030 |
|
Historical Period |
2018 - 2023 |
|
Base Year |
2024 |
|
Forecast period |
2025 - 2030 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2030 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Segments covered |
Animal type, product, indication, end use, region |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
|
Country scope |
U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
|
Key companies profiled |
Merck & Co., Inc (Animal Health; Dechra; Animalcare Limited; B. Braun Vet Care (B Braun SE); Elanco Animal Health Incorporated (Animal Health; Zoetis Inc. |
|
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
|
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
Global Veterinary Intravenous Solutions Market Report Segmentation
Product Outlook (Revenue, USD Million; 2018 - 2030)
-
-
Isotonic crystalloids
-
Synthetic colloids
-
Blood products
-
Dextrose solutions
-
Parenteral nutrition
-
-
Indication Outlook (Revenue, USD Million; 2018 - 2030)
-
Diabetic Ketoacidosis
-
Pancreatitis
-
Anthrax
-
Chronic Kidney Disease
-
Others
-
-
Animal Type Outlook (Revenue, USD Million; 2018 - 2030)
-
Companion Animals
-
Production Animals
-
-
End Use Outlook (Revenue, USD Million; 2018 - 2030)
-
Veterinary Hospitals
-
Research Institutes
-
Others
-
-
Regional Outlook (Revenue, USD Million; 2018 - 2030)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
Rest of Europe
-
-
Asia Pacific
-
Japan
-
India
-
China
-
South Korea
-
Australia
-
Thailand
-
Rest of APAC
-
-
Latin America
-
Brazil
-
Argentina
-
Rest of LATAM
-
-
Middle East and Africa (MEA)
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
Rest of MEA
-
-
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy